LP352 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
140	ドラベ症候群	2
144	レノックス・ガストー症候群	2

140. ドラベ症候群

---

臨床試験数 : 116 /  薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05626634 (ClinicalTrials.gov)	November 8, 2022	15/11/2022	Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: LP352	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 2	United States
2	NCT05364021 (ClinicalTrials.gov)	March 3, 2022	22/3/2022	Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox Gastaut Syndrome	Drug: LP352;Drug: Placebo	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 1/Phase 2	United States

144. レノックス・ガストー症候群

---

臨床試験数 : 111 /  薬物数 : 72 - (DrugBank : 14) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 61

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05626634 (ClinicalTrials.gov)	November 8, 2022	15/11/2022	Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: LP352	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 2	United States
2	NCT05364021 (ClinicalTrials.gov)	March 3, 2022	22/3/2022	Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox Gastaut Syndrome	Drug: LP352;Drug: Placebo	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 1/Phase 2	United States